![]() ![]() It is EHRA/ESC policy to sponsor position papers and guidelines without commercial support, and all members volunteered their time. Relationships with industry and other conflicts The pharmacologic and non-pharmacologic antiarrhythmic approaches discussed may, therefore, include drugs that do not have the approval of governmental regulatory agencies in all countries. Overall, this is a consensus document that includes evidence and expert opinions from several countries. The categorization used should not be considered as being directly similar to that used for official society guideline recommendations which apply a classification (I–III) and level of evidence (A, B, and C) to recommendations. European Heart Rhythm Association grading of consensus statements does not have separate definitions of Level of Evidence. Treatment strategies for which there has been scientific evidence that they are potentially harmful and should not be used are indicated by a red heart. May be supported by randomized trials that are, however, based on small number of patients to allow a green heart recommendation. A yellow heart indicates that general agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure. Thus, a green heart indicates a recommended/indicated treatment or procedure and is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. 3 We have, therefore, opted for an easier and, perhaps, more user-friendly system of ranking that should allow physicians to easily assess current status of evidence and consequent guidance ( Table 1). Current systems of ranking level of evidence are becoming complicated in a way that their practical utility might be compromised. ![]() The document was peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, and SOLAECE.Ĭonsensus statements are evidence-based, and derived primarily from published data. This document was prepared by the Task Force with representation from EHRA, HRS, APHRS, and SOLAECE. In controversial areas, or with regard to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberations. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as are frequency of follow-up and cost-effectiveness. Members of the Task Force were asked to perform a detailed literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. This document summarizes current developments in the field, with focus on new advances since the last ESC guidelines, and provides general recommendations for the management of SVT patients based on the principles of evidence-based medicine. To address this topic, a Task Force was convened by the European Heart Rhythm Association (EHRA) with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE), with the remit to comprehensively review the published evidence available, and to publish a joint consensus document on the management of SVT patients, with up-to-date consensus recommendations for clinical practice. In addition, several associated conditions where SVTs may co-exist need to be explained in more detail. There is a need to provide expert recommendations for professionals participating in the care of patients presenting with SVT. The European Society of Cardiology published management guidelines for supraventricular tachycardias (SVT) in 2003, 1 and corresponding US guidelines have also been published, the most recent being in 2015. Supraventricular arrhythmias are common, and patients are often symptomatic requiring management with drug therapies and electrophysiological procedures. Supraventricular tachycardia in pregnancy 498 Supraventricular tachycardia in adult congenital heart disease 496 The asymptomatic patient with ventricular pre-excitation 495 Wolff–Parkinson–White syndrome and atrioventricular reentrant tachycardias 492Ĭoncealed and other accessory pathways 494 Non-paroxysmal junctional tachycardia 492Ītrioventricular reentrant tachycardias 492 Relationships with industry and other conflicts 467ĭifferential diagnosis of tachycardias 469Īcute management in the absence of an established diagnosis 475Īcute management of narrow QRS tachycardia 478Īcute management of wide QRS tachycardia 479Ītrioventricular junctional tachycardias 489Ītrioventricular nodal reentrant tachycardia 489 ![]()
0 Comments
Leave a Reply. |